Andrew Scharenberg
Amministratore Delegato presso Umoja Biopharma, Inc.
Provenienza dei contatti di primo grado di Andrew Scharenberg
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts.
43
| Private Company | Investment Managers | 43 |
| Public Company | Biotechnology | 22 | |
Umoja Biopharma, Inc.
 Umoja Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Umoja Biopharma, Inc. engages in the development of immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. It offers an integrated cellular immunotherapy platform comprising VivoVec in vivo delivery, RACR/CAR synthetic receptor payload and TumorTag targeting technologies that attack cancer cells. The company was founded by Michael Jensen, Philip Low, Andy Scharenberg and Ryan Crisman and is headquartered in Seattle, WA.
8
| Holding Company | Pharmaceuticals: Major | 8 |
Casebia Therapeutics LLC
 Casebia Therapeutics LLC Pharmaceuticals: GenericHealth Technology Casebia Therapeutics LLC is a joint venture company that focuses on discovering, developing, and commercializing gene-editing therapeutics to treat genetic causes of bleeding disorders and autoimmune diseases. The company is based in Cambridge, MA.
2
| Joint Venture | Pharmaceuticals: Generic | 2 |
UNC School of Medicine
1
| College/University | Other Consumer Services | 1 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Andrew Scharenberg tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal President | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Private Equity Investor | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| BAYER AG | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| IDENIX PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal General Counsel Corporate Officer/Principal | |
Idun Pharmaceuticals, Inc.
 Idun Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Idun Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the discovery and development of human therapeutics to control apoptosis. The company was founded by John C. Reed, Robert H. Horvitz, and Lawrence C. Fritz in March 1993 and is headquartered in San Diego, CA. | Medical Specialties | Director/Board Member Founder | |
| RADIUS HEALTH, INC. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| CHIASMA, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer | |
Clinical Ink, Inc.
 Clinical Ink, Inc. Internet Software/ServicesTechnology Services Clinical Ink, Inc. provides electronic source solutions for clinical research sites. Its solutions include data management, monitoring, clinical sites and patient centric. The company was founded by Douglas E. Pierce Jr. and Tommy Littlejohn on July 19, 2006 and is headquartered in Winston-Salem, NC. | Internet Software/Services | Director/Board Member Director/Board Member Director/Board Member | |
| Dartmouth College | College/University | Doctorate Degree Doctorate Degree Undergraduate Degree | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Corporate Officer/Principal Doctorate Degree Masters Business Admin Doctorate Degree Undergraduate Degree Undergraduate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
| Boston University | College/University | Masters Business Admin Masters Business Admin Undergraduate Degree | |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Consultant / Advisor Chief Executive Officer Private Equity Analyst | |
| Massachusetts Institute of Technology | College/University | Undergraduate Degree Graduate Degree Corporate Officer/Principal Doctorate Degree Corporate Officer/Principal Doctorate Degree Graduate Degree Doctorate Degree Undergraduate Degree Doctorate Degree | |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Undergraduate Degree Undergraduate Degree | |
| Tufts University | College/University | Corporate Officer/Principal Doctorate Degree | |
| Princeton University | College/University | Undergraduate Degree Undergraduate Degree Corporate Officer/Principal Doctorate Degree | |
University of Minnesota
 University of Minnesota Other Consumer ServicesConsumer Services Digi-Key Corp. distributes electronic components. It also distributes semiconductors, discrete, electromechanical parts. Its products include audio products, batteries, cable assemblies, capacitors, computer & video accessories, connectors, crystals & oscillators, discrete semiconductor products and many more. The company was founded by Ronald A. Stordahl in 1972 and is headquartered in Thief River Falls, MN. | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree | |
| AVEO PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| Harvard Medical School | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Graduate Degree Doctorate Degree Graduate Degree Doctorate Degree | |
Amphivena Therapeutics, Inc.
 Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Drugstore Chains | Founder Director/Board Member Director/Board Member | |
TriNetX, LLC
 TriNetX, LLC Medical/Nursing ServicesHealth Services TriNetX, Inc. provides an online data network for collaborative research. It enables hospitals, academic medical centers, physician networks, practices, and pharmaceuticals to participate in collaborative research and a public and private sustainability model for research informatics. The company was founded by Bard Geesaman in 2013 and is headquartered in Cambridge, MA. | Medical/Nursing Services | Director/Board Member Director/Board Member Director/Board Member | |
| EVELO BIOSCIENCES, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Private Equity Investor | |
Tizona Therapeutics, Inc.
 Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Biotechnology | Founder Director/Board Member Director/Board Member | |
| ONCORUS, INC. | Biotechnology | Chairman Chief Executive Officer Director/Board Member | |
iOmx Therapeutics AG
 iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | Biotechnology | Director/Board Member Founder Director/Board Member | |
| TCR2 THERAPEUTICS INC. | Pharmaceuticals: Major | Chairman Director/Board Member Founder Director of Finance/CFO Chief Operating Officer | |
Maverick Therapeutics, Inc.
 Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | Biotechnology | Founder Founder Director/Board Member | |
| ALLOVIR, INC. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer Director/Board Member Chief Executive Officer | |
| REPARE THERAPEUTICS INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
CODA Biotherapeutics, Inc.
 CODA Biotherapeutics, Inc. Medical SpecialtiesHealth Technology CODA Biotherapeutics, Inc. engages in the development of chemo genetic neuromodulation platform for the treatment of severe neurological disorders. The company was founded by Mitchell H. Finer, Allan Basbaum, Nicholas Boulis, Joseph Glorioso III and Kenneth P. Greenberg in 2014 and is headquartered in South San Francisco, CA. | Medical Specialties | Director/Board Member Founder | |
Triplet Therapeutics, Inc.
 Triplet Therapeutics, Inc. Medical/Nursing ServicesHealth Services Triplet Therapeutics, Inc. develops therapy for huntington's , myotonic dystrophy, spin cerebellar ataxias and repeated expansion diseases. The company was founded by Jean-François Formela and Nessan Bermingham is headquartered in Cambridge, MA. | Medical/Nursing Services | Director/Board Member Director/Board Member President | |
| WEREWOLF THERAPEUTICS, INC. | Pharmaceuticals: Major | Founder Founder Director/Board Member Chief Operating Officer | |
| ITEOS THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Nextpoint Therapeutics, Inc.
 Nextpoint Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nextpoint Therapeutics, Inc. is a biotech company based in Cambridge, MA. The company is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The company's innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Nextpoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies. Detlev Biniszkiewicz has been the CEO of the company since 2018. | Miscellaneous Commercial Services | Chairman Director/Board Member Chairman Director/Board Member Director/Board Member | |
Orna Therapeutics, Inc.
 Orna Therapeutics, Inc. BiotechnologyHealth Technology Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes. | Biotechnology | Chairman Director/Board Member Director/Board Member Chief Executive Officer Director/Board Member | |
| TURMERIC ACQUISITION CORP. | Financial Conglomerates | Chief Executive Officer Director of Finance/CFO President Director/Board Member Chairman Chief Operating Officer | |
| CULLINAN THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member Founder Director of Finance/CFO Director/Board Member | |
Aktis Oncology, Inc.
 Aktis Oncology, Inc. Medical/Nursing ServicesHealth Services Aktis Oncology, Inc. is a biotechnology company located in Boston, MA. The company specializes in the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. The company's molecules are designed for high tumor penetration and long residence time, which maximizes tumor elimination while minimizing side effects of treatment. The approach enables clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Founded and incubated by MPM Capital, Aktis Oncology has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Matt M. Roden has been the CEO of the company since 2020. | Medical/Nursing Services | Chairman Chief Executive Officer Corporate Officer/Principal | |
| 2SEVENTY BIO, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Investor Relations Contact Chief Tech/Sci/R&D Officer | |
Bioimpact Capital LLC
 Bioimpact Capital LLC Investment ManagersFinance MPM BioImpact LLC (MPM BioImpact) is a venture capital firm a subsidiary of MPM Bioimpact Inc founded in 1996. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor Private Equity Investor Consultant / Advisor Director of Finance/CFO Private Equity Investor Private Equity Investor Private Equity Investor Consultant / Advisor Private Equity Investor Private Equity Investor Private Equity Investor Director/Board Member | |
Crossbow Therapeutics, Inc.
 Crossbow Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Crossbow Therapeutics, Inc. is a biotechnology company that aims to improve the lives of people with cancer by developing next-generation immunotherapies. The company is based in Cambridge, MA, and the CEO of the company is Briggs W. Morrison. The company's T-bolt™ therapies are designed to target previously unreachable cancer cell targets with high precision. Crossbow's approach is efficient and selective, allowing them to target the entire universe of cancer proteins, which expands the potential of antibody therapy to address many types of cancer. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer Chief Executive Officer | |
Reunion Neuroscience, Inc.
 Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Renagade Therapeutics, Inc.
 Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | Biotechnology | Founder Director/Board Member Founder | |
Semma Therapeutics, Inc.
 Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Director/Board Member Chief Executive Officer |
Statistiche
Distribuzione geografica
| Stati Uniti | 47 |
| Germania | 3 |
| Canada | 3 |
Settori
| Health Technology | 32 |
| Consumer Services | 9 |
| Finance | 6 |
| Health Services | 4 |
| Technology Services | 2 |
Posizioni
| Director/Board Member | 391 |
| Corporate Officer/Principal | 160 |
| Independent Dir/Board Member | 95 |
| Undergraduate Degree | 68 |
| Private Equity Investor | 67 |
Contatti più connessi
| Insiders | |
|---|---|
| Steven Gillis | 58 |
| Ansbert Gadicke | 56 |
| Luke Evnin | 42 |
| Todd Foley | 38 |
| Thomas Ebeling | 33 |
| Dieter Weinand | 32 |
| Edward Hurwitz | 27 |
| Mitchell Finer | 26 |
| Briggs Morrison | 26 |
| John Hamer | 24 |
| Robert Tepper | 24 |
| Anthony Adam Rosenberg | 23 |
| Mark Vachon | 19 |
| Patrick Baeuerle | 19 |
| Roger Jeffs | 18 |
- Borsa valori
- Insiders
- Andrew Scharenberg
- Connessioni Società
